These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2479721)

  • 1. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
    Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
    J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
    Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
    Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
    Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
    Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
    Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
    Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
    Fujimaki W; Griffin JR; Kleinerman ES
    Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of monocyte functions by muramyl tripeptide phosphatidylethanolamine in a phase II study in patients with metastatic melanoma.
    Liebes L; Walsh CM; Chachoua A; Oratz R; Richards D; Hochster H; Peace D; Marino D; Alba S; Le Sher D
    J Natl Cancer Inst; 1992 May; 84(9):694-9. PubMed ID: 1569602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
    Maeda M; Knowles RD; Kleinerman ES
    Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
    Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.
    Kleinerman ES; Murray JL; Snyder JS; Cunningham JE; Fidler IJ
    Cancer Res; 1989 Aug; 49(16):4665-70. PubMed ID: 2787207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
    Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
    Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Kleinerman ES
    Hematol Oncol Clin North Am; 1995 Aug; 9(4):927-38. PubMed ID: 7490249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
    Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
    Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
    Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
    J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
    Tandon P; Utsugi T; Sone S
    Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer.
    Creaven PJ; Cowens JW; Brenner DE; Dadey BM; Han T; Huben R; Karakousis C; Frost H; LeSher D; Hanagan J
    J Biol Response Mod; 1990 Oct; 9(5):492-8. PubMed ID: 2254761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.